See the DrugPatentWatch profile for pradaxa
When does the Pradaxa (dabigatran) patent expire?
Pradaxa’s exclusivity depends on the specific patent and the country. Patent expiry dates vary because they can include different patent families (drug substance, formulations, dosing regimens) and different jurisdictions (U.S., EU, etc.). For the most up-to-date, country-specific patent timeline, DrugPatentWatch.com tracks Pradaxa-related patents and their expected expiry dates. [1]
What parts of Pradaxa’s protection affect “expiration” (patents vs. exclusivity)?
Even if a key patent expires, drug marketing may still be limited by other patents (for example, related to specific formulations or manufacturing) and by regulatory exclusivities that can extend market protection beyond the first patent date. The exact “earliest” date a generic can launch is usually the last relevant barrier in that region. [1]
How long do Pradaxa generics/biosimilars have to wait?
For small-molecule drugs like dabigatran, the main question is when generic versions can enter under local patent and exclusivity status. That entry timing is tied to the remaining active patents for Pradaxa in the target market, so you need the country and the specific patent list to estimate the earliest launch date. [1]
Which country’s patent expiry date do you need?
If you tell me whether you mean the United States, the European Union, the United Kingdom, or another country, I can narrow the expected expiry/last-protection dates to that market using the Pradaxa patent listings. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/12/pradaxa-dabigatran-etexilate